呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

中国新生儿肺表面活性物质临床应用专家共识(2021版)

2021-08-12 中华医学会儿科学分会新生儿学组 中华儿科杂志

新生儿呼吸窘迫综合征

肺表面活性物质(PS)是治疗新生儿呼吸窘迫综合征的常规药物,但有关PS的适应证、用药时机、剂量和次数、给药技术、疗效评估等一直在不断研究和发展。

中文标题：

中国新生儿肺表面活性物质临床应用专家共识(2021版)

发布机构：

中华医学会儿科学分会新生儿学组

发布日期：

2021-08-12

简要介绍：

肺表面活性物质(PS)是治疗新生儿呼吸窘迫综合征的常规药物,但有关PS的适应证、用药时机、剂量和次数、给药技术、疗效评估等一直在不断研究和发展。为使PS临床应用更加规范,中华医学会儿科学分会新生儿学组和中华儿科杂志编辑委员会组织专家以国内外循证医学证据和最新进展为基础,制定中国新生儿PS临床应用专家共识。

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1082383, encodeId=f5431082383f4, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:48:03 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067744, encodeId=f641106e74481, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db35100454, createdName=181*****048<手机用户>7545, createdTime=Sun Nov 07 09:18:19 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053371, encodeId=93c710533e1a1, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/e3f9329c15f34d8391ef6f67a02d7bcf/9352767971cf44e38122b1a325c39e0d.jpg, createdBy=12565019949, createdName=294147823, createdTime=Mon Sep 20 22:52:30 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-12-21 龙珠

    学习好资料！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1082383, encodeId=f5431082383f4, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:48:03 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067744, encodeId=f641106e74481, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db35100454, createdName=181*****048<手机用户>7545, createdTime=Sun Nov 07 09:18:19 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053371, encodeId=93c710533e1a1, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/e3f9329c15f34d8391ef6f67a02d7bcf/9352767971cf44e38122b1a325c39e0d.jpg, createdBy=12565019949, createdName=294147823, createdTime=Mon Sep 20 22:52:30 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-11-07 181*****048<手机用户>7545

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1082383, encodeId=f5431082383f4, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:48:03 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067744, encodeId=f641106e74481, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db35100454, createdName=181*****048<手机用户>7545, createdTime=Sun Nov 07 09:18:19 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053371, encodeId=93c710533e1a1, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/e3f9329c15f34d8391ef6f67a02d7bcf/9352767971cf44e38122b1a325c39e0d.jpg, createdBy=12565019949, createdName=294147823, createdTime=Mon Sep 20 22:52:30 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-09-20 294147823

    受益匪浅

    0